Breast Cancer – Geographic Focus: China – Breast Cancer – China In-Depth (China)

Breast cancer is the most commonly diagnosed cancer in Chinese women. With a high incidence and prolonged treatment duration, breast cancer presents a lucrative commercial opportunity for drug manufacturers. Over the last few years, the drug-treatment rate for breast cancer in China has increased owing to the availability of novel, premium-priced, targeted therapies (e.g., pertuzumab [Roche’s Perjeta]) and the inclusion of these agents in the National Reimbursement Drug List. Based on the strong late-phase pipeline, we expect more new agents to launch for breast cancer in China during the forecast period. Additionally, in view of ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies will be increasingly encouraged to enter this market.


  • How large is China’s drug-treatable breast cancer population, and how will drug-treatment rates change during the forecast period?·
  • Which are the most commercially relevant drugs in China’s breast cancer market, and why? What are interviewed experts’ insights into current treatment options?·
  • What are the market access considerations for key therapies in the breast cancer pipeline in China? What sales could these agents secure in breast cancer? What are interviewed experts’ opinions of key emerging therapies?·
  • What are the key drivers and constraints in China’s breast cancer therapy market, and how will the market evolve over the forecast period?


China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

Release date

June 2021



Primary Research

Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with hematologist-oncologists. Supported by survey data collected for this and other Clarivate research.


Diagnosed incidence of breast cancer in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations


10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.


Phase III/PR: 10+ drugs; Phase II: 10+ drugs; coverage of select Phase I products.

Table of contents

  • Breast Cancer - Geographic Focus: China - Breast Cancer - China In-Depth (China)
    • Breast Cancer - China In-Depth (China)